Follow-up of the Cardiomyopathy Cohort SFB/TR19

Follow-up of the Inflammatory Cardiomyopathy Cohort of SFB/TR19

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02971267

Acronym

SFB/TR19plus

Enrollment

150

Registered

2016-11-22

Start date

2015-06-30

Completion date

2025-12-31

Last updated

2021-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiomyopathies, Heart Failure

Keywords

heart failure, cardiomyopathy, myocarditis

Brief summary

Follow-up of a cohort of inflammatory cardiomyopathy patients (suspected or validated inflammatory cardiomyopathy) recruited at baseline by the SFB-TR19 project. Standardized protocols will be used for the assessment of medical history and examinations, laboratory biomarkers, and the collection of various biomaterials for biobanking purposes.

Detailed description

Periodical follow-up of a cohort of inflammatory cardiomyopathy patients (suspected or validated inflammatory cardiomyopathy) recruited at baseline by the SFB/TR19 project. Participants will be followed up at least every year - or more frequently based on clinical need. Standardized protocols will be used for the assessment of medical history and examinations, laboratory biomarkers, and the collection of various biomaterials for biobanking purposes.

Interventions

OTHERObservational

None, observational only

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Participation in baseline examination of SFB/TR19

Exclusion criteria

* none

Design outcomes

Primary

Measure	Time frame	Description
Number of cardiovascular events	1-year follow-ups up to 10 years	Number of hospitalization (HF based. all-cause), interventions (ICD, pacemaker), myocardial infarction

Secondary

Measure	Time frame	Description
LVEF (left ventricular ejection fraction)	1-year follow-ups up to 10 years	Left ventricular ejection fraction at time of follow-ups (through study completion, every year)
VO2peak	1-year follow-ups up to 10 years	Exercise capacity by CPET (cardiopulmonary exercise testing)
QOL	1-year follow-ups up to 10 years	Quality of life by MLHF questionnaire
Mortality	1-year follow-ups up to 10 years	Mortality (HF-related, cardiovascular disease, all-cause mortality)

Countries

Germany

Contacts

Primary ContactMarcus Dörr, MD

mdoerr@uni-greifswald.de+49383486

Backup ContactStephan B Felix, MD

felix@uni-greifswald.de+49383486

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026